What is the primary purpose of this 10-Q filing?

This 10-Q filing serves as Eli Lilly & Co.'s official quarterly report to the U.S. Securities and Exchange Commission (SEC). Its primary purpose is to provide investors and the public with updated financial information, performance trends, and material business developments for the period ending September 29, 1994.

Where can I find the detailed financial results for Eli Lilly in this filing?

The provided text is a directory listing of the filing. To find the detailed financial results, including the income statement, balance sheet, cash flow statement, and management's discussion and analysis (MD&A), you would need to access the full 10-Q document from the SEC's EDGAR database or other financial data providers.

What are the key financial metrics an investor should look for in this report?

Investors should look for key metrics such as revenue growth (both overall and by product segment), gross profit margins, operating income, net income, earnings per share (EPS), cash flow from operations, and any significant changes in the company's balance sheet, such as debt levels or working capital.

Does this filing contain information about new drug developments or clinical trials?

Typically, the 'Management's Discussion and Analysis of Financial Condition and Results of Operations' section of a 10-Q filing would discuss significant product developments, regulatory updates, research and development activities, and other factors that could materially affect the company's future financial performance. This specific directory listing does not contain that detail.

LLY 10-Q Filed Nov 10, 1994

Summary

Eli Lilly & Co. (LLY) filed its 10-Q for the period ending September 29, 1994, on November 9, 1994. This report provides a snapshot of the company's financial performance and position during the third quarter of 1994. Investors should focus on key financial metrics and any disclosed business developments that could impact future profitability and strategic direction. While the provided text is a directory listing of the SEC filing and does not contain the detailed financial statements or management discussion and analysis, it indicates the filing is available. Investors seeking to understand Lilly's performance for this period would need to access the full 10-Q document to review revenue trends, profitability, balance sheet health, and any forward-looking statements or risk factors. The filing date suggests it captures performance trends leading into the crucial year-end reporting period.

Key Highlights

1Company: Eli Lilly & Co. (LLY)
2Filing Type: 10-Q (Quarterly Report)
3Reporting Period End Date: September 29, 1994
4Filing Date: November 9, 1994
5Indicates a routine quarterly financial disclosure to investors.
6Key information for investors would be within the full financial statements and MD&A, not present in the directory listing.
7This filing provides a mid-year update on the company's operational and financial standing.

ELI LILLY & Co Quarterly Report for Q3 Ended Sep 30, 1994

Summary

Key Highlights

Frequently Asked Questions